Filing Flows › Indivior Pharmaceuticals (INDV) › Q3 2026
Indivior Pharmaceuticals (INDV) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 29, 2026
Indivior Pharmaceuticals (INDV) reported revenue of $356M for the third quarter 2026 (Q3 2026), +13% from a year earlier and +4% from the quarter before. Operating margin was 50.6%, net earnings $137M (38.5% of revenue).
Indivior Pharmaceuticals, Q3 2026: revenue $356M (+13% year over year), operating margin 50.6%, net earnings $137M, operating cash flow $97.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $356M | +4% | +13% |
| Gross profit | $305M | +4% | +33% |
| Operating profit | $180M | +12% | +319% |
| Net earnings | $137M | +12% | +226% |
| Operating cash flow | $97.0M | -58% | — |
| Free cash flow | $83.0M | -63% | — |
What changed
Revenue was $356.0M in Q3 2026, up 13% year over year and up 4% from the previous quarter.
Gross margin was 85.7%, up 12.4 points from Q3 2025. Operating profit was $180.0M, a 50.6% margin (up 36.9 points year over year). Of the extra revenue versus Q3 2025, 326% reached operating profit, above the 14% margin then. Operating expenses fell 33% while revenue rose 13%. Net earnings were $137.0M, up 226% year over year. The effective tax rate was 24.7%.
Operating cash flow was $97.0M, 71% of net earnings. Non-cash charges added back $1.0M of depreciation and amortization and $8.0M of share-based compensation. Working capital and other items used $49.0M. Capital expenditures of $14.0M left free cash flow of $83.0M.
Questions
What was Indivior Pharmaceuticals' revenue in the third quarter 2026?
Indivior Pharmaceuticals (INDV) reported revenue of $356M for the third quarter 2026 (Q3 2026), +13% from a year earlier and +4% from the quarter before.
Was Indivior Pharmaceuticals profitable in the third quarter 2026?
Operating profit was $180M (50.6% of revenue) and net earnings $137M.